Objective To assess the representativeness of National Cancer Patient Experience Survey (CPES) responders compared with the English cancer registry population in term of age, sex, socioeconomic deprivation, ethnicity, disease stage and median survival. Design Population-based case-control study. Setting England. Population We identified 103 186 colorectal, lung, breast and prostate cancer patients responding to at least one survey during 2010-2014 and randomly selected one non-responder from the cancer registry matched on cancer type and yearly quarter of diagnosis. Main outcome measure We compared age, sex, socioeconomic deprivation, ethnicity and disease stage between the two groups using logistic regression. We also compared survival (in years) using the Mann-Whitney test. Results Across all cancer types survey responders were younger, more likely to have a White ethnic background, to be resident in less deprived areas and diagnosed with earlier stage disease although they varied between cancers. Median survival for responders was also higher than for the cancer registry population (colorectal: 4.8 vs 3.2; lung: 2.0 vs 0.3; breast: 5.7 vs 5.4; and prostate: 5.7 vs 5.2 years; all p-values<0.001). Conclusion CPES responders with the four most common cancers do not necessarily represent all patients with these cancers in terms of demographic characteristics and tumour stage at diagnosis. These limitations should be considered when interpreting findings. To capture the experiences of patients currently underrepresented in CPES, different approaches may need to be taken.
Bibliographical noteFunding Information:
1Cancer Epidemiology, Population and Global Health, Comprehensive Cancer Centre, Faculty of Life Sciences & Medicine, King's College London, London, UK 2College of Health Science, Public Health Section, Saudi Electronic University, Riyadh, Saudi Arabia 3Consumer Forum, NCRI CSG (Lung) Subgroup, BTOG Steering Committee, NHSE CEG, National Cancer Research Institute, London, UK 4Consumer Involvement Advisory Group, Consumer Forum, National Cancer Research Institute, London, UK 5National Cancer Registration and Analysis Service, Public Health England, London, UK
© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
- Patient experience